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Objective: To verify whether absolute monocyte count (AMC) and lymphocyte- monocyte ratio (LMR) at
diagnosis are valid prognostic parameters in classical Hodgkin lymphoma (cHL).
Patients and Methods: Data were collected from 1450 patients with cHL treated in Israel and Italy from
January 1, 1988, through December 31, 2007.
Results: The median age of the patients was 33 years (range, 17-72 years), and 70% (1017) of the patients
had nodular sclerosis (NS); the median follow-up duration was 87 months. The best cutoff value for AMC
was 750 cells/mm3, and the best ratio for LMR was 2.1. The adverse prognostic impact of an AMC of more
than 750 cells/mm3 was conﬁrmed for the entire cohort, and its clinical signiﬁcance was particularly evident
in patients with NS histology. The progression-free survival (PFS) at 10 years for an AMC of more than 750
cells/mm3 was 65% (56%-72%), and the PFS at 10 years for an AMC of 750 cells/mm3 or less was 81%
(76%-84%; P<.001). The overall survival (OS) at 10 years for an AMC of more than 750 cells/mm3 was 78%
(70%-85%), and the OS at 10 years for an AMC of 750 cells/mm3 or less was 88% (84%-90%; P¼.01). In
multivariate analysis, both AMC and LMR maintained prognostic signiﬁcance for PFS (hazard ratio
[HR], 1.54, P¼.006, and HR, 1.50, P¼.006) after adjusting for the international prognostic score, whereas
the impact on OS was conﬁrmed (HR, 1.56; P¼.04) only in patients with NS and an AMC of more than 750
cells/mm3.
Conclusion: This study conﬁrms that AMC has prognostic value in cHL that is particularly signiﬁcant in
patients with NS subtype histology. This ﬁnding links the known impact of macrophages and monocytes
in Hodgkin lymphoma with routine clinical practice.
ª 2015 Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). n Mayo Clin Proc. 2015;90(6):756-764C urrent therapy for classical Hodgkinlymphoma (cHL) cures about 80%of the patients with this disease,
whereas the rest relapse or are refractory to
therapy. Major efforts have been made to avoid
possible overtreatment and potential long-term
toxicity in younger patients and to identify
patients requiring more aggressive therapy in
order to avoid the development of refractory
disease. In this regard, to deﬁne a scoring sys-
tem that could stratify patients, and possibly
even predict outcome, would be both helpfulMayo Clin Proc. n June 2015
edings.org n ª 2015 Mayo Foundation for Medical Education and Rand practical to apply in daily practice. The
international prognostic score (IPS) proposed
in 19981 uses a model that incorporates 7 prog-
nostic factors at initial diagnosis to predict
outcome in patients with cHL. The major limi-
tation of the IPS relates to the fact that it was
ﬁrst proposed for advanced cHL in an attempt
to avoid overtreatment in some patients and
identify others in whom standard therapy
would be inadequate. However, its role in
both favorable and unfavorable early stage
disease is limited.;90(6):756-764 n http://dx.doi.org/10.1016/j.mayocp.2015.03.025
esearch. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 1. Clinical and Laboratory Characteristics
of the 1450 Patients Included in the Study
Variable
Median (2.5th-97.5th
percentile)
Age (y) 33 (17-72)
Hemoglobin (g/dL) 12.4 (7.9-16.1)
WBC (cells/mm3) 8600 (3200-20,000)
AMC (cells/mm3) 550 (82-1527)
ALC (cells/mm3) 1543 (334-3981)
LMR 2.8 (0.7-17)
Albumin (g/dL) 4.0 (2.4-5.0)
Variable n (%)
Age >45 y 402 (28)
Sex: male 728 (50)
Stage IV disease 234 (16)
Hemoglobin <10.5 g/dL 253 (17)
Albumin <4 g/dL 846 (58)
WBC >15,000 cells/mm3 157 (11)
ALC <600 cells/mm3 90 (6)
Histology, NS 1017 (70)
Systemic symptoms 640 (44)
IPS
0-2 1054 (73)
3-7 396 (27)
ALC ¼ absolute lymphocyte count; AMC ¼ absolute
monocyte count; IPS ¼ international prognostic score; LMR ¼
lymphocyte-monocyte ratio; NS ¼ nodular sclerosis; WBC ¼
white blood cell.
AMC AND LMR PREDICT OUTCOME IN HODGKIN LYMPHOMAAn absolute lymphocyte count (ALC) of less
than 600 cells/mm3 or less than 8% of the total
white blood cell (WBC) count is one of the factors
included in the IPS and is regarded as an impor-
tant prognostic parameter inﬂuencing the inter-
val of freedom from progression.1 Indeed, ALC
is considered a surrogate biomarker of tumor-
inﬁltrating lymphocytes and reﬂects the general
status of host immunity. Recently, however,
several studies have reported that absolutemono-
cyte count (AMC) at diagnosis also has prog-
nostic value in lymphomas.2-7 The rationale for
using AMC as a prognostic parameter in cHL is
even more relevant than in other malignancies
because of the immunohistochemical andmolec-
ular data, including gene expression proﬁle,
which identify a key role for monocytes andmac-
rophages in the biology of cHL, particularly in
patients with nodular sclerosis (NS) histology.8-12
Combining AMC and ALC as a lymphocyte-
monocyte ratio (LMR) has been proposed and
shown to have prognostic potential in both
non-Hodgkin lymphoma (NHL) and cHL.13,14
Each of the above studies has used different cutoffMayo Clin Proc. n June 2015;90(6):756-764 n http://dx.doi.org/10.1
www.mayoclinicproceedings.orgvalues for AMC and LMR, which are easily acces-
sible and simple to apply, but an agreed standard
value has as yet not been deﬁned.
The aim of the present study was to verify,
using a large cohort of patients from 2 coun-
tries and continents, whether AMC and LMR
represent valid prognostic parameters in cHL
and at the same time identify the best cutoff
value for AMC and LMR.
PATIENTS AND METHODS
This study is a retrospective analysis of previ-
ously untreated patients with cHL.We reviewed
clinical and laboratory data of “therapy-naive”
patients, treated in different centers from
January 1, 1988, to December 31, 2007, in Israel
and Italy. Italian cases were retrieved from 38
centers belonging to the Gruppo Italiano Studio
Linfomi archive. Data from Israeli patients were
collected from 2 medical centers after approval
by local institutional review boards. All studies
were performed in accordance with the princi-
ples of the Declaration of Helsinki.
Patients were accepted into this study if the
following criteria were fulﬁlled: histopathological
diagnosis of cHL, no previous therapy, age more
than 18 years, no human immunodeﬁciency
virus infection, availability of data on all clinical
and laboratory features and treatments given, as
well as outcome, and follow-up. The database
contained a total of 1848 patients who had
received combination chemotherapy with or
without radiotherapy. Analysis was performed
on a ﬁnal cohort of 1450 patients after the exclu-
sion of those with missing data relating to IPS
(n¼166), or monocyte count (n¼137), or
missing reports (n¼95). Deﬁnition of response
was based on guidelines revisedbyCheson et al.15
Primary end points of the study were to
assess the impact of AMC, ALC, and LMR on
progression-free survival (PFS) and overall sur-
vival (OS). The secondary end point was to estab-
lish the best cutoff value for AMC and LMR on
the basis of different values reported in the
literature.
AMC and ALC Adjusted to the IPS
Absolute monocyte count and ALC were
adjusted to the IPS1 used to predict survival
in patients with advanced cHL. The IPS is
based on 7 adverse clinical and laboratory pa-
rameters: age more than 45 years, albumin less
than 4 g/dL, ALC of less than 600 cells/mm3 or016/j.mayocp.2015.03.025 757
TABLE 2. Treatment According to the Chemo-
therapy Regimens Used With or Without Radio-
therapy and Response Ratesa,b
Treatment
n (%)
RT, no RT, yes Total
Chemotherapy, n (%)
ABVD 268 (40) 394 (60) 662 (46)
MEC/MAC 219 (62) 134 (38) 353 (24)
VBM 54 (20) 213 (80) 267 (18)
BEACOPP 53 (60) 65 (40) 88 (6)
Stanford V 16 (36) 29 (64) 45 (3)
EVE 4 (11) 31 (89) 35 (2)
RT 836 (58)
Response CHT  RT n (%)
CR 1298 (90)
PR 48 (3)
SD 34 (2)
PD 50 (4)
Early failure/withdrawal 20 (1)
aABVD ¼ adriamycin, bleomycin, vinblastine, and dacarbazine;
BEACOPP ¼ bleomycin, etoposide, adriamycin, cyclophos-
phamide, vincristine, procarbazine, and prednisone; CR ¼
complete response; EVE ¼ epirubicin, vinblastine, and etopo-
side; MAC ¼ mechlorethamine, vincristine, procarbazine,
prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine,
doxorubicin, and vindesine; MEC ¼ mechlorethamine, lomus-
tine, vindesine, melphalan, prednisone, epidoxorubicin, vincris-
tine, procarbazine, vinblastine and bleomycin; PD¼ progression
disease; PR¼ partial response; RT¼ radiotherapy; SD¼ stable
disease; Stanford V ¼ doxorubicin, vinblastine, mechloreth-
amine, vincristine, bleomycin, etoposide, and prednisone;
VBM ¼ vinblastine, bleomycin, and methotrexate.
bPercentage of RT expressed by row.
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FIGURE 1. Kaplan-Meier curves forOS and PFS for the cohort of 1450 patients
entered in the study. OS ¼ overall survival; PFS ¼ progression-free survival.
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758 Mayo Clin Proc. n June 2015less than 8% of the WBC count, hemoglobin
level of less than 10.5 g/dL, male sex, and leuko-
cytosis (WBC count>15,000 cells/mm3).
Statistical Analyses
Progression-free survival was measured from the
date of study entry to either the last follow-up or
the occurrence of one of the following events:
disease progression, relapse, or death from any
cause. Continuous variables were reported as
the median and 2.5th to 97.5th percentile.
Comparisons were performed with the Mann-
Whitney test or the Kruskall-Wallis test. Cate-
gorical variables were reported as proportions
and compared with the chi-square test or the
exact Fisher test.
Survival was assessed by the Kaplan-Meier
estimates16 and compared by risk groups using
the log-rank test and the Cox proportional haz-
ards model.17 The proportional hazard assump-
tion was veriﬁed graphically by means of scaled
Schoenfeld residuals.18 The effect size was re-
ported as hazard ratio (HR) with the associated
95% CI.
We assessed the optimal cutoff for AMC and
LMR using the maximum log-rank statistic and
by means of receiver operating characteristic
(ROC) curve analysis at 5-year follow-up.
We evaluated the following cutoff values
for monocytes in cHL: 500, 630,14,19 750,20
800, and 900 cells/mm3.21 For LMR, we also
studied several cutoff values based on data in
the literature and our own experience with
statistical analysis including 1.1,14,19 1.5,20
2.1,6 2.8, and 3.5.2
Thereafter, we chose cutoff levels that had
the best discriminating power to distinguish
patients with good outcome from those with
worse outcome, after adjusting for IPS values.
Attempts to deﬁne the different cutoffs were
checked using HRs and the respective z score
(from theWald test) and by comparing the abil-
ity to enforce the discriminating power (ROC
curve analysis at 5-year follow-up), adding
the AMC or the LMR to the IPS score (delta [dif-
ference] of area under the curve between ROC
curve analysis at 5-year follow-up with IPS and
IPS þ AMC or LMR [dAUC]).
Given the broad agreement in the literature
regarding the deﬁnition of lymphopenia as an
ALC of 600 cells/mm3, we decided to use this
level as our optimal lymphocyte cutoff, whereas
analysis of different cutoff points was done only;90(6):756-764 n http://dx.doi.org/10.1016/j.mayocp.2015.03.025
www.mayoclinicproceedings.org
TABLE 3. Multiple Cox Regression Analysis for AMC > 750 Cells/mm3 Adjusted
by IPS Parameters for Patients with Classical Hodgkin Lymphoma and Nodular
Sclerosis Histology: Progression-Free Survival and Overall Survivala
AMC Cutoff n (%) HR (95% CI) P dAUC Pb
500 636 (44) 1.00
>500 814 (56) 1.20 (0.96-1.49) .104 þ0.4 .70
630 908 (63) 1.00
>630 542 (37) 1.38 (1.11-1.71) .004 þ1.5 .11
750 1091 (75) 1.00
>750 359 (25) 1.47 (1.17-1.86) .001 þ1.7 .05
800 1140 (79) 1.00
>800 310 (21) 1.38 (1.08-1.76) .010 þ1.1 .19
900 1232 (85) 1.00
>900 218 (15) 1.29 (0.97-1.71) .075 þ0.4 .53
LMR Cutoff n (%) HR (95% CI) P dAUC Pb
>1.1 1328 (92) 1.00
1.1 122 (8) 1.35 (0.95-1.92) .099 þ0.4 .46
>1.5 1180 (81) 1.00
1.5 270 (19) 1.55 (1.21-2.00) .001 þ1.2 .11
>2.1 957 (66) 1.00
2.1 493 (34) 1.49 (1.20-1.86) <.001 þ2.2 .02
>2.8 739 (51) 1.00
2.8 711 (49) 1.30 (1.05-1.61) .017 þ1.1 .28
>3.0 656 (45) 1.00
3.0 794 (55) 1.45 (1.16-1.80) .001 þ1.6 .10
aAMC ¼ absolute monocyte count; AUC ¼ area under the curve; dAUC ¼ delta (difference) of
AUC between ROC curve analysis at 5-y follow-up with IPS and IPS þ AMC or LMR; HR ¼
hazard ratio; IPS ¼ international prognostic score; LMR ¼ lymphocyte-monocyte ratio; ROC ¼
receiver operating characteristic.
bP value of the delta over 1000 bootstrap resamples.
AMC AND LMR PREDICT OUTCOME IN HODGKIN LYMPHOMAfor AMC and LMR. All statistical tests were
2-sided.
RESULTS
Patients’ Characteristics
The median age at diagnosis for the entire
cohort of 1450 patients was 33 years (range,
17-72 years); 50% (728) were males, and 44%
(640) presented with systemic symptoms. In
terms of cHL subtype, NS was diagnosed in
70% of the patients (1017). Other clinical char-
acteristics and those included in the IPS are pre-
sented in Table 1.
Details of therapy are summarized in Table 2.
All patients were treated with combination
chemotherapy and considering the reference
treatment (adriamycin, bleomycin, vinblastine,
and dacarbazine), other types of regimens given
had no impact on the PFS (score test from Cox
regression model, P¼.78) and the OS (score
test, P¼.37). A total of 836 (58%) patients
received radiotherapy in addition to chemo-
therapy, and of the entire cohort, 90% (1298
patients) of the patients achieved complete
remission.
The median follow-up for the entire cohort
of 1450 patients was 87 months (range, 1-243
months). The estimated 5- and 10-year OS
was 90% (95% CI, 88%-91%) and 83%
(95% CI, 80%-85%), respectively. A total of
201 deaths were recorded; of these, 67%
(135) were from progressive disease and
15% (30) due to second cancers. The PFS at
5 and 10 years was 79% (95% CI, 77%-
81%) and 74% (95% CI, 71%-76%), respec-
tively (Figure 1).
Considering the period of diagnosis 1988 to
1999 as reference, the periods 2000 to 2003 and
2004 to 2007 did not show an effect on the PFS
(score test from Cox regression model, P¼.37)
and the OS (score test, P¼.41).
Cutoff Value for AMC
Absolutemonocyte countwas taken from thepre-
treatment complete blood cell counts recorded at
diagnosis of cHL. The median AMC for all pa-
tients was 550 cells/mm3 (2.5th-97.5th percen-
tile, 82-1527 cells/mm3). Absolute monocyte
count was higher in patients older than 45 years
(P¼.007) and in patients with a WBC count of
more than15,000cells/mm3 (P<.001),NShistol-
ogy (P<.001), and an IPS of 3 to 7 (P¼.009). In
Mayo Clin Proc. n June 2015;90(6):756-764 n http://dx.doi.org/10.1
www.mayoclinicproceedings.orgthe reported literature, the most common AMC
cutoff levels evaluated were more than 500,2
630,19,22,23 750,20 800, and 900 cells/mm3.21
Our optimal cutoff level on the PFS taken from
the ROC curve analysis at 5-year follow-up was
749 cells/mm3 (ROC curve¼0.56) and with
maximal log-rank test was 748 cells/mm3
(c2¼13.8). Thus, all these proposed thresholds
were analyzed for PFS by means of the estimated
HR (in the univariate Cox model) and the dAUC
after adding AMC to IPS 3 to 7. The best cutoff
value was seen with an AMC of more than 750
cells/mm3 (HR, 1.47; 95% CI, 1.17-1.86) and
dAUC of 1.7 (P¼.05) (Table 3).
Three hundred ﬁfty-nine patients (25%)
were enrolled with an AMC of more than
750 cells/mm3, compared with 1091 patients
(75%) with an AMC of 750 cells/mm3 or less
at diagnosis. The 5-year PFS was 81% (95%
CI, 79%-83%) for an AMC of 750 cells/mm3
or less and 74% (95% CI, 69%-78%) for an016/j.mayocp.2015.03.025 759
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760AMC of more than 750/mm3 (log-rank test,
P¼.001).
The OS for the entire cohort, according to an
AMCof 750 cells/mm3 or less andmore than 750
cells/mm3, was 91% (95% CI, 89%-92%) and
86% (95% CI, 82%-90%), with an HR of 1.35
(95% CI, 0.99-1.84; P¼.06), respectively.
In patients with NS cHL, the 5- and 10-year
PFS was 81% (95% CI, 78%-84%) and 77%
(95% CI, 74%-80%), respectively, whereas the
OS was 91% (95% CI, 89%-93%) after 5-year
follow-up and 85% (95% CI, 82%-88%) after
10-year follow-up (Figure 2).
Thus, by using the peripheral blood AMC,
we were able to discriminate patients with less
favorable outcome, with a PFS of 81% (95%
CI, 76%-84%) for those with an AMC of 750
cells/mm3 or less compared with 65% (95% CI,
56%-72%) for those with an AMC of more
than 750 cells/mm3 at 10 years (P¼.001)
(Figure 3). The OS was 88% (95% CI, 84%-
90%) in those with an AMC of 750 cells/mm3
or less compared with 78% (95% CI, 70%-
85%) in those with an AMC of more than 750
cells/mm3 at 10 years (P¼.01) (Figure 3). After
adjusting for the IPS, the AMC had clinical
prognostic signiﬁcance in patients with NS
(HR, 1.54, 95% CI, 1.23-2.10, P¼.006 for PFS;
HR, 1.56, 95% CI, 1.02-2.40, P¼.04 for OS) as
reported in Table 4. CI)
 CI)
5-y
81 (78-84)
91 (89-93)
10-y
77 (74-80)
85 (82-88)
4 5 6
Follow-up (y)
7 8 9 10 11 12
1 752 658 557 465 374 312 239 176 129
9 669 593 502 423 342 286 218 161 116
curves for OS and PFS for the cohort of 1017
erosis Hodgkin lymphoma histology. OS ¼ overall
on-free survival.
Mayo Clin Proc. n June 2015Cutoff Value for ALC
The ALC was derived from pretreatment
complete blood cell count at diagnosis, and
for all patients the median ALC was 1543
cells/mm3 (2.5th-97.5th percentile, 334-
3981). The accepted IPS cutoff value of 600
cells/mm3 for ALC and lymphopenia was deﬁned
as in the formal scoring system. Of the entire
cohort, only 92 patients (6%) presented with
lymphopenia at the time of diagnosis.Cutoff Value for LMR
The LMR was obtained by dividing the ALC by
the AMC taken from the complete peripheral
blood count at diagnosis. The median LMR for
all patients was 2.8 (2.5th-97.5th percentile,
0.7-17). The LMR was lower in patients with
stage IV disease (P<.001), a hemoglobin level
of less than 10.5 g/dL (P<.001), a WBC count
of 15,000 cells/mm3 (P<.001), an albumin level
of 4 g/dL (P<.001), with NS histology
(P<.001), and an IPS of 3 to 7 (P¼.009). For
LMR, we also tested several cutoff values based
on the literature data including 1.1,14,19 1.5 ,20
2.1,6,22 2.8, and 3.5.2 Our optimal cutoff on
PFS from the ROC curve analysis at 5-year
follow-up was 2.1 (ROC curve¼0.56) and
with maximally log-rank test was 1.5/mm3
(c2¼16.7). All these proposed thresholds were
analyzed for PFS using the estimated HR (in
the univariate Cox model) and the dAUC after
adding LMR to IPS 3 to 7. The most promising
cutoff value for LMR was 2.1, with an HR of
1.49 (95% CI, 1.20-1.86) and dAUC of 2.2
(P¼.02) (Table 3).
Four hundred ninety-three patients (34%)
were enrolled with an LMR of 2.1 or less
compared with 957 patients (66%) with an
LMR of more than 2.1 at diagnosis, with a 5-
year PFS of 74% (95% CI, 70%-78%) and 82%
(95% CI, 80%-85%), respectively (P¼.001).
The OS for those with an LMR of more
than 2.1 and 2.1 or less was 91% (95% CI,
89%-92%) and 88% (95% CI, 84%-91%),
respectively, with an HR of 1.29 (95% CI,
0.97-1.72, P¼.08).
An LMR of less than 2.1 was shown to have a
higher risk in terms of PFS (HR, 1.69; 95% CI,
1.28-2.22; P¼.001) and OS (HR, 1.53; 95%
CI, 1.05-2.22; P¼.03) for patients with histolog-
ical subtype. After adjusting for IPS and NS his-
tology, the HR was 1.50 (95% CI, 1.12-2.00;;90(6):756-764 n http://dx.doi.org/10.1016/j.mayocp.2015.03.025
www.mayoclinicproceedings.org
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FIGURE 3. Kaplan-Meier curves for OS and PFS for the cohort of 1017
patients with nodular sclerosis Hodgkin lymphoma histology based on an
AMC of  or >750 cells/mm3. AMC ¼ absolute monocyte count; OS ¼
overall survival; PFS ¼ progression-free survival.
TABLE 4. Multiple Cox Regression Analysis for AMC > 750 Cells/mm3 and
Adjusted by IPS Parameters for Patients With Classical Hodgkin’s Lymphoma
and Nodular Sclerosis Histology for PFS and OS
Factor
PFS, HR (95% CI)
P
OS, HR (95% CI)
PUnivariate Univariate
AMC >750 cells/mm3 1.68 (1.26-2.24) <.001 1.66 (1.12-2.45) .01
Multivariate Multivariate
AMC >750 cells/mm3 1.54 (1.23-2.10) .006 1.56 (1.02-2.40) .04
Age > 45 y 1.63 (1.20-2.22) .002 2.59 (1.76-3.81) <.001
Sex: male 1.09 (0.83-1.44) .52 1.01 (0.69-1.47) .98
Stage IV disease 1.24 (0.87-1.76) .24 1.29 (0.81-2.06) .28
Albumin <4 g/dL 1.20 (0.88-1.63) .26 1.38 (0.89-2.14) .15
Hemoglobin <10.5 g/dL 1.67 (1.19-2.32) .003 1.49 (0.95-2.34) .08
WBC >15,000 cells/mm3 1.39 (0.94-2.06) .10 1.53 (0.91-2.57) .11
ALC <600 cells/mm3 1.20 (0.65-2.10) .60 1.55 (0.78-3.08) .22
ALC ¼ absolute lymphocyte count; AMC ¼ absolute monocyte count; HR ¼ hazard ratio; IPS ¼
international prognostic score; OS ¼ overall survival; PFS ¼ progression-free survival; WBC ¼
white blood cell.
AMC AND LMR PREDICT OUTCOME IN HODGKIN LYMPHOMAP¼.006) for PFS, whereas for OS it was less sig-
niﬁcant with an HR of 1.27 (95% CI, 0.85-1.88;
P¼.239) (Figure 4).
DISCUSSION
Recently, the AMC and its ratio with the ALC
at diagnosis (LMR) have been used as prog-
nostic parameters to identify high-risk patients
with lymphoma.2-4,6 Although cutoff values
reported in the various studies differed, similar
results were obtained by different working
groups, indicating that monocytosis or lym-
phopenia at diagnosis has an adverse impact
on survival in patients with HL and NHL.
Lymphopenia is a well-recognized prog-
nostic marker in advanced cHL, and it is
included as one of the criteria of the IPS.1 In
NHL, ALCs have been evaluated already and
decreased levels have been shown to be associ-
ated with worse OS.22 In cHL, lymphopenia is
formally deﬁned as an ALC of 600 cells/mm3
or less, whereas in some of the studies on lym-
phoma this value was deﬁned differently and
the cutoff generally used was 1000 cells/mm3
or less lymphocytes.4 In our study, only 6%
of the entire cohort had an ALC of less than
600 cells/mm3 and because of this, we did
not relate to this parameter. The biology under-
lying the adverse signiﬁcance of lymphopenia
has not been extensively investigated; however,
this ﬁnding probably relates to host character-
istics and is regarded as an indicator of
impaired immunity, which may contribute to
tumorigenesis and subsequent tumor growth.
In the present study of a very large cohort of
patients with cHL, we demonstrate that AMC
(cutoff value of 750 cells/mm3) has prognostic
signiﬁcance in terms of PFS and OS in patients
with cHL with NS histology. Our results are in
keeping with those of other recent studies, evalu-
ating the convenient clinical application of AMC
as a simple prognostic parameter in cHL.13,21
Here, we conﬁrm our earlier results2,20 ob-
tained in a smaller patient cohort, and also verify
those reported by other study groups.7,13,21 In
our view, this study has several advantages over
other earlier reports. First, it was performed in a
very large cohort of patients with cHL; second, re-
sults were obtained on both binational andmulti-
center levels, not from a single center in one
country; third, we performed a comprehensive
analysis to select the best cutoff for AMC in
cHL, testing a wide range of all previouslyMayo Clin Proc. n June 2015;90(6):756-764 n http://dx.doi.org/10.1
www.mayoclinicproceedings.orgproposed values. Furthermore, we chose cutoff
values that showed the best discriminating power
for distinguishing patient outcome, after adjust-
ing for IPS and histological subtype. In our large
patient cohort, an AMC of more than 750 cells/
mm3 had a statistically signiﬁcant adverse impact
on outcome after both univariate (P<.001) and
multivariate analyses (P¼.006) in patients with
NS. These results validate our earlier observations
showing that this parameter can beused routinely
to evaluate newly diagnosed patients with cHL016/j.mayocp.2015.03.025 761
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FIGURE 4. Kaplan-Meier curves for OS and PFS for the cohort of 1017
patients with nodular sclerosis Hodgkin lymphoma histology based on an
LMR of  or >2.1. LMR ¼ lymphocyte to monocyte ratio; OS ¼ overall
survival; PFS ¼ progression-free survival.
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762and identify higher-risk patients with a worse
outcome. This AMC value can be combined
meaningfully with our best cutoff for LMR
(>2.1) and can also be applied to daily clinical
practice. In addition, our results demonstrated
that a lower LMRwas associatedwithworst prog-
nostic factors such as stage IV disease, a hemoglo-
bin level of less than 10.5, an IPS of 3 to 7, aWBC
count of more than 15,000 cells/mm3, and an al-
bumin level of less than4g/dL, indicating that this
parameter not only correlateswith host immunity
(ALC) and tumor microenvironment (AMC) but
also may indirectly serve as a measurement of tu-
mor growth and tumor “mass.”
In1978, Schechter and Soehnlen24 described
the role ofmonocytes in the pathogenesis of cHL,
but investigations of the clinical association with
macrophages andmonocytes have been reported
only more recently.8,11,12 Using gene expression
proﬁling, Steidl et al8 identiﬁed a gene signature
of tumor-associated macrophages (TAMs) that
is signiﬁcantly associated with primary treatment
failure. In this important study, now a landmark
in understanding of the biology of cHL, 80% of
the samples used were of NS subtype, implying
that in addition to being the most frequent histo-
logical subtype encountered it may have the
best association with macrophage/monocyte
biology.12 Others have also shown that the pres-
ence of TAMswithin the tumor itself predicted an
inferior outcome in cHL.11,25,26 In our study, weMayo Clin Proc. n June 2015also identiﬁed that AMC had the greatest signiﬁ-
cance in terms of PFS and OS in this subgroup of
patientswith cHLwithNShistopathology. In this
respect, monocytes and their total number, as re-
ﬂected by AMC in the peripheral blood count,
may indeed be regarded as a surrogate biomarker
of TAMs within the tumor microenvironment.
Epstein-Barr virus is also known to play a role
in the development of HL, and Kamper et al9
demonstrated that TAMs correlate with not
only adverse prognosis but also Epstein-Barr vi-
rus status in patients with cHL. This observation
lends further support for the suggestion that the
microenvironment plays an important role in
lymphomagenesis and prognosis of lymphoma.
The most sensitive imaging modality to
deﬁne the site of involvement in HL and to
assess response to therapy is positron emission
tomographyecomputed tomography (PET-CT)
scan. This imaging modality has become the cri-
terion standard guide in the management of cHL,
and is usually performed at diagnosis (for
baseline information on sites of disease and
initial tumor volume), and after 2 cycles as
an interim analysis and a guide for continuing
or changing therapy. Very recently it has been
reported to have predictive value, even if per-
formed after 1 cycle of chemotherapy,27,28
and methods for assessing and measuring to-
tal tumor volume are currently improving
signiﬁcantly.29 It seems most appropriate
that combined analysis of the total PET-CT
uptake and quantitation of the AMC in pa-
tients with cHL will serve as a combination
of valuable surrogate markers for detecting
disease activity. It is of interest to note that
Touati et al10 have recently reported pioneer-
ing studies demonstrating that increases in
CD68-positive TAMs predict an unfavorable
outcome in cHL, when correlated with interim
ﬂuorodeoxyglucose-positron emission tomogra-
phy (PET) assessment. In this respect, analysis
regarding the role of AMC in combination with
PET-CT data has already been reported to be
considerable in NHL.30
Several markers other than AMC, ALC,
and LMR have been examined and reported
to have prognostic signiﬁcance in cHL.31
These include the expression of COX-2 on
Reed-Sternberg cells,31 insulin-like growth fac-
tor 1 receptor expression,32 and levels of IL-
1033 and/or other cytokines.34 The main limi-
tation of recording these important markers;90(6):756-764 n http://dx.doi.org/10.1016/j.mayocp.2015.03.025
www.mayoclinicproceedings.org
AMC AND LMR PREDICT OUTCOME IN HODGKIN LYMPHOMAroutinely relates to the fact that results are not
readily reproducible in all laboratories and
appear to be very variable, particularly for
levels of relevant cytokines. In contrast to
this, one of the obvious advantages favoring
the routine use of AMC is its simplicity and
that it can be calculated easily and routinely
in all laboratories.
Our study has some obvious limitations,
including the fact that it is retrospective and
that patients were not treated uniformly, but
with different chemotherapy combinations.
However, all regimens used appeared to induce
similar overall response rates, and as a result we
are of the opinion that this variable has a negli-
gible inﬂuence on our results.CONCLUSION
In this study of cHL we conﬁrm that AMC at
diagnosis has prognostic value and can iden-
tify about 25% of the cases with adverse
outcome. It has a major impact on survival,
particularly in patients with NS histology. Its
signiﬁcance is also maintained when examined
in correlation with IPS, and appears to be in-
dependent of the clinical stage of the disease.ACKNOWLEDGMENTS
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